Metrics as of 10/15/2026, 10:58 AM (Berlin time), refresh in progress.
Prime Medicine Stock
Prime Medicine, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Allan Reine
- Employees
- 146
- Market cap
- $568 M
- IPO
- 20/10/2022
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and…
Prime Medicine stock: price history
1D
-5.7%
1W
-19.7%
1M
-1.6%
6M
-17.4%
YTD
-9.8%
1Y
-47.7%
2Y
-16.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~5% stronger price swings than usual
Prime Medicine stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Prime Medicine is a biotechnology company specializing in the development of gene therapies. At its core is the proprietary Prime Editing platform, a technology that combines a hybrid protein consisting of a Cas protein and the enzyme reverse transcriptase with a specific pegRNA. This system enables highly precise modifications at exactly defined sites in the genome to treat various diseases. The business model focuses on leveraging this technological platform to develop novel therapeutic approaches.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Prime Medicine
Analyst assessment of Prime Medicine
PRICE TARGET LOW
US$6.00
CONSENSUS
US$7.50
MEDIAN
US$7.50
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
7
BUY
3
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 25/09/2026
Prime Medicine stock metrics
P/E
-2.85
P/B
13.93
EV/EBITDA
-3.51
RETURN ON EQUITY
-105.8%
NET MARGIN
-3,649.0%
DEBT/EQUITY
2.83
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
32.8%
FLOAT SHARES
59,420,914
AVG. DAILY VOLUME (30D)
4,208,428
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.7%
Forums (Reddit)
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Prime Medicine stock
What does Prime Medicine do?
Prime Medicine, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Allan Reine, the company employs around 146 people.
The IPO was on 20/10/2022; the stock trades on NASDAQ under the ticker PRME.
What do analysts say about Prime Medicine stock?
10 analysts rate the stock, the consensus is Buy (as of 25/09/2026).
The average price target is US$7.50, ranging from US$6.00 to US$9.00, with a median of US$7.50.
This is an external assessment, not a statement by Market Jury.
When does Prime Medicine report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Prime Medicine pay a dividend?
Yes. The last dividend was US$0.01 per share, ex-date 22/03/2018, paid on 29/03/2018.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Prime Medicine?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Prime Medicine stock analyzed?
Clicking "Analyze stock" lets five strategies assess Prime Medicine against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.